A virulent vasculopathy

Allograft Vasculopathy Versus Atherosclerosis Antibody and Complement in Transplant Vasculopathy Cytokines, Interferon- , and Transplant Vasculopathy Chemokines and Transplant Vasculopathy Stem Cells and Transplant Vasculopathy

Advances in immunosuppression have decreased the incidence of acute rejection, but the development of vasculopathy in the coronary arteries of transplants continues to limit the survival of cardiac allografts. Transplant vasculopathy has also been referred to as accelerated graft arteriosclerosis because it has features of arteriosclerosis, but it is limited to the graft and develops over a per...

Cardiac allograft vasculopathy: a review.

Cardiac allograft vasculopathy (CAV) is a major factor limiting long-term survival after cardiac transplantation. CAV is an accelerated form of coronary artery disease (CAD) that is characterized by concentric fibrous intimal hyperplasia along the length of coronary vessels. Both immunologic and nonimmunologic risk factors contribute to the development of CAV by causing endothelial dysfunction ...

A Case of Lividoid Vasculopathy.

4 year old female presented with non-healing ulcers on both the legs since 5 years. She was being treated by general surgeon with broad spectrum ant ib iot ic coverage and repeated debridements. Plastic surgeon was also consulted. On examination the ulcers were around the malleolus, painful, irregular in shape with erythematous margins and the floor was covered with necrotic slough. The surroun...

Characterization of a Highly Virulent Infectious Bursal Disease Virus

Allograft Vasculopathy

Ma Cardiac allograft vasculopathy (CAV) remains the Achilles’ heel of long-term survival after heart transplantation. Almost one-third of patients develop CAV by 5 years post-transplant and 1 in 8 deaths beyond a year are due to CAV. Abnormal vascular fibroproliferation in CAV occurs as a result of coronary endothelial inflammation, injury, and dysfunction triggered by immune and nonimmune insu...